...Sure. I'll be -- I'll try my best to be brief. I know these are -- all of these are going to come up in Q&A. Look, I have been at Sarepta now about 6.5 years. Ian's been a few more years than me. We've had a very mild Sarepta milestone, driven period of time that Sarepta a lot of really important moments. But there are no more important moments than the moments we've had in 2023. It has been a very successful year for us thus far, and we have a lot to do in a very short period of time for the rest of the year. As you all know, we had an approval for what I believe will be the most significant in vivo gene therapy so far, which is ELEVIDYS with a limited label, and we've launched that. That launch is going exceptionally well right now. Our goal is to broaden that label as rapidly as possible. I am very happy to tell you that, of course, EMBARK is the basis for broadening that label. Our last patient, last visit in EMBARK will occur this week. So we are in great shape. We've said some time...
